{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:31:09Z","timestamp":1792593069241,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001396.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T00:00:00Z","timestamp":1370563200000}}],"reference-count":136,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001396.pub3","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T00:57:15Z","timestamp":1370566635000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Selective serotonin reuptake inhibitors for premenstrual syndrome"],"prefix":"10.1002","author":[{"given":"Jane","family":"Marjoribanks","sequence":"first","affiliation":[{"name":"University of Auckland; Obstetrics and Gynaecology; Park Rd Grafton Auckland New Zealand 1003"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Brown","sequence":"additional","affiliation":[{"name":"University of Auckland; Obstetrics and Gynaecology; Park Rd Grafton Auckland New Zealand 1003"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Michael Shaughn","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Keele University Medical School; Academic Department of Obstetrics and Gynaecology; North Staffordshire Hospital, City General Hospital Newcastle Road Stoke-on-Trent Staffordshire UK ST4 6QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Wyatt","sequence":"additional","affiliation":[{"name":"Peninsula College of Medicine and Dentistry; Institute of Health Service Research; St Lukes Exeter UK EX1 2LU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,7]]},"reference":[{"key":"10.1002\/14651858.CD001396.pub3-BIB0001|cit1","first-page":"S28","article-title":"Relationship and response of food cravings and depression to sertraline in patients with premenstrual syndrome","volume":"October","author":"Arredondo-Soberon","year":"1997","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0924-977X(01)80189-9","article-title":"Efficacy of intermittent fluoxetine dosing in premenstrual dysphoric disorder (PMDD)","volume":"11 Suppl 3","author":"Cohen","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub3-BIB0003|cit3","first-page":"435","article-title":"Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo controlled, clinical trial using computerized diaries","volume":"100","author":"Cohen","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0004|cit4","unstructured":"Cohen L Soares C Yonkers K Paroxetine controlled release (CR) is effective in the treatment of premenstrual dysphoric disorder (PMDD): Results from a randomized placebo controlled trial 15th Annual US Psychiatric and Mental Health Congress. October 28- November 3rd. Las Vegas, Nevada 2002 Abstract 39"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0005|cit5","first-page":"204","article-title":"Intermittent fluoxetine dosing in premenstrual dysphoric syndrome","volume":"2 Suppl","author":"Judge","year":"2001","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0006|cit6","first-page":"87","article-title":"Predictors of response to luteal phase fluoxetine treatment of PMDD","volume":"5 Suppl","author":"Miner","year":"2002","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0007|cit7","first-page":"111","article-title":"Paroxetine controlled release is effective in treating premenstrual dysphoric disorder","volume":"101 Suppl 4","author":"Cohen","year":"2003","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.psy.0000140005.94790.9c","article-title":"Paroxetine controlled release for premenstrual dysphoric disorder: A double blind, placebo controlled trial","volume":"66","author":"Cohen","year":"2004","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0010|cit9","unstructured":"GlaxoSmithKline A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg\/day and 25 mg\/day) for Premenstrual Dysphoric Disorder http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F677&studyId=3742A8A5-2C3C-4A40-B9B5-7975DF70CF53&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0009|cit10","unstructured":"GlaxoSmithKline NZ Phone call from a representative of GlaxoSmithKline New Zealand (in response to an email sent by J Marjoribanks) confirming that 29060\/677 (Cohen 2004) and 29060\/689 (Pearlstein 2005) were separate studies July 2012"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0011|cit11","unstructured":"Pearlstein 2012 Email to Jane Marjoribanks from Teri Pearlstein advising that participants in Pearlstein 2005 and Cohen 2004 did not, to her knowledge, overlap."},{"key":"10.1002\/14651858.CD001396.pub3-BIB0012|cit12","unstructured":"Crnobaric C Jasovic-Gasic M Milanovanic S Miljevic C Treatment of premenstrual dysphoric disorder with fluoxetine during the luteal phase 9th Congress of the Association of European Psychiatrists Copenhagen, Denmark"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0893-133X(94)00076-C","article-title":"The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome","volume":"12","author":"Eriksson","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/JCP.0b013e3181678a28","article-title":"Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder","volume":"28","author":"Eriksson","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/archpsyc.56.10.932","article-title":"Differential response to antidepressants in women with premenstrual syndrome","volume":"56","author":"Freeman","year":"1999","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.ajp.161.2.343","article-title":"Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder","volume":"161","author":"Freeman","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archgenpsychiatry.2008.547","article-title":"Time to relapse after short-term or long-term sertraline treatment for severe premenstrual syndromes","volume":"66","author":"Freeman","year":"2009","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0018|cit18","unstructured":"Freeman E Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study NCT00523705 http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00523705"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0019|cit19","unstructured":"GlaxoSmithKline A Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety and Tolerability of Paroxetine in Patients with Premenstrual Dysphoric Disorder. http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F400&studyId=80268FE4-8DB0-4A5A-8CF4-51162DA5EE83&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0020|cit20","unstructured":"GlaxoSmithKline A Multicentre, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Paroxetine (5mg OD Vs 10mg OD Vs 20mg OD) in Patients with Premenstrual Dysphoric Disorder (PMDD) http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F427&studyId=46B83DBA-A3AD-44FB-84F7-51BC66679F35&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0021|cit21","unstructured":"GlaxoSmithKline A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg\/day and 25 mg\/day) for Premenstrual Dysphoric Disorder http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F688&studyId=4EAE38F8-954D-453B-BA8C-32CA4FFAD277&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4088\/JCP.v58n0905","article-title":"Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome","volume":"58","author":"Halbreich","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0023|cit23","first-page":"248","article-title":"Intermittent (luteal phase) dosing of sertraline effective in PMDD","volume":"3 Suppl 1","author":"Halbreich","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0024|cit24","unstructured":"Halbreich U Bergeron R Stout A Freeman E Yonkers K Pearlstein T Dosing of sertraline is effective in premenstrual dysphoric disorder 155th Annual Meeting of the American Psychiatric Association"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub3-BIB0025|cit25","first-page":"1219","article-title":"Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder","volume":"100","author":"Halbreich","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jad.2004.10.004","article-title":"Pretreatment pattern of symptom expression in premenstrual dysphoric disorder","volume":"85","author":"Pearlstein","year":"2005","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/archfami.8.4.328","article-title":"Luteal phase sertraline for the treatment of premenstrual dysphoric disorder","volume":"8","author":"Jermain","year":"1999","journal-title":"Archives of Family Medicine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0028|cit28","unstructured":"Kornstein S Gillespie J Double blind placebo controlled study of sertraline in premenstrual syndrome 155th Annual Meeting of the American Psychiatric Association. May 18-23, Philadelphia PA 2002 NR248"},{"issue":"10","key":"10.1002\/14651858.CD001396.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v67n1020","article-title":"Low dose sertraline in the treatment of moderate to severe premenstrual syndrome: Efficacy of 3 dosing strategies","volume":"67","author":"Kornstein","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0030|cit30","unstructured":"Bellew KM Landen M Hunter B McCafferty JP Social functioning improves with paroxetine treatment 155th Annual Meeting of the American Psychiatric Association. May 18-23, Philadelphia 2002 NR282"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0031|cit31","unstructured":"GlaxoSmithKline A Placebo-Controlled Study to Investigate the Efficacy of Intermittent and Continuous Treatment With Paroxetine in Patients With Premenstrual Dysphoric Disorder (PMDD) http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F658&studyId=186F6412-CDE1-4505-8ACD-FBB1858393EB&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0033|cit32","unstructured":"Landen M Sorvik K Ysander C Allgulander C Nissbrandt H Gezelius B A placebo controlled trial exploring the efficacy of paroxetine for the treatment of premenstrual dysphoria American Psychiatric Association, 155th annual meeting. May 18-23 Philadelphia, PA. 2002"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0034|cit33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0924-977X(01)80424-7","article-title":"A placebo controlled study of the efficacy of intermittent and continuous treatment with paroxetine for premenstrual dysphoric disorder (PMDD)","volume":"11 Suppl 3","author":"Landen","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0035|cit34","unstructured":"Landen MSG A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00516113 2007"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0032|cit35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.npp.1301216","article-title":"Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder","volume":"32","author":"L\u00e4nden","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"6489","key":"10.1002\/14651858.CD001396.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/bmj.305.6849.346","article-title":"Fluoxetine treatment of severe premenstrual syndrome","volume":"305","author":"Menkes","year":"1992","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-199300820-00003","article-title":"Fluoxetine treatment of severe premenstrual syndrome","volume":"8","author":"Menkes","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0149-2918(02)85043-3","article-title":"Weekly luteal phase dosing with enteric coated fluoxetine 90mg in premenstrual dysphoric disorder: A randomised, double blind, placebo controlled clinical study","volume":"24","author":"Miner","year":"2002","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0039|cit39","first-page":"87","article-title":"Predictors of response to luteal phase fluoxetine treatment of PMDD","volume":"5 Suppl","author":"Miner","year":"2002","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0301-2115(97)02741-3","article-title":"Fluoxetine in the treatment of premenstrual syndrome","volume":"73","author":"Ozeren","year":"1997","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004714-199708000-00004","article-title":"Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dsyphoric disorder","volume":"17","author":"Pearlstein","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0043|cit42","unstructured":"GlaxoSmithKline A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg\/day and 25 mg\/day) for Premenstrual Dysphoric Disorder http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F689&studyId=6F9A5C75-99C3-4F11-AED7-A122263D1746&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0042|cit43","unstructured":"GlaxoSmithKline NZ Phone call from a representative of GlaxoSmithKline New Zealand (in response to an email sent by J. Marjoribanks) confirming that 29060\/677 (Cohen 2004) and 29060\/689 (Pearlstein 2005) were separate studies July 2012"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0044|cit44","unstructured":"Pearlstein 2012 Email to Jane Marjoribanks from Teri Pearlstein advising that participants in Pearlstein 2005 and Cohen 2004 did not, to her knowledge, overlap."},{"key":"10.1002\/14651858.CD001396.pub3-BIB0045|cit45","unstructured":"Pearlstein T Bellew K Endicott J Steiner M Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double blind, placebo controlled trial 41st Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0020-7292(00)80655-4","article-title":"Fluoxetine improves social functioning in women with premenstrual dysphoria","volume":"70 Suppl 3","author":"Dillon","year":"2000","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0047|cit47","first-page":"178","article-title":"Efficacy of fluoxetine in improving mood symptoms and social impairments in patients with PMDD","volume":"42","author":"Koke","year":"2001","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0020-7292(00)82820-9","article-title":"Fluoxetine's efficacy in improving mood. physical and social impairment symptoms associated with PMDD","volume":"Abstract Book 3","author":"Nilsson","year":"2000","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0049|cit49","unstructured":"Steiner M Babcock S McCray SD Romano S Fluoxetine's efficacy in improving premenstrual dysphoric disorder 152nd Annual Meeting of the American Psychiatric Association, Washington DC. USA"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0050|cit50","unstructured":"Steiner M Babcock S Steinberg SI Stewart DE Carter D Berger C Fluoxetine's efficacy in improving physical symptoms associated with pdd: results from a multisite, randomized placebo controlled trial 152nd Annual Meeting of the American Psychiatric Association. Washington DC USA"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00737-002-0162-2","article-title":"Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder","volume":"6","author":"Steiner","year":"2003","journal-title":"Archives of Women's Mental Health"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0052|cit52","unstructured":"Steiner M Judge R Brown E Dillon J Fluoxetine improves social functioning in women with premenstrual dysphoric disorder (PMDD) International Journal of Neuropsychopharmacology 2000 247"},{"issue":"4","key":"10.1002\/14651858.CD001396.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"D147","DOI":"10.1016\/S0020-7292(00)84685-8","article-title":"Fluoxetine's effect on food craving during the luteal phase in women with premenstrual dysphoric disorder (PMDD)","volume":"70","author":"Steiner","year":"2000","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0054|cit54","first-page":"208","article-title":"Fluoxetine's efficacy in improving physical symptoms associated with PMDD","volume":"9 Suppl 5","author":"Steiner","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0055|cit55","first-page":"208","article-title":"Fluoxetine's efficacy in improving physical symptoms associated with PMDD","volume":"Suppl","author":"Steiner","year":"2001","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0306-5456(00)00120-0","article-title":"The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder","volume":"108","author":"Steiner","year":"2001","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0057|cit57","first-page":"208","article-title":"Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD","volume":"Suppl","author":"Steiner","year":"2001","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM199506083322301","article-title":"Fluoxetine in the treatment of premenstrual dysphoric disorder","volume":"332","author":"Steiner","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0924-977X(00)80154-6","article-title":"Premenstrual dysphoric disorder (PMDD) and work efficiency: Response to fluoxetine in a randomized clinical trial","volume":"10","author":"Steiner","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0060|cit60","first-page":"226","article-title":"Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial","volume":"Suppl","author":"Steiner","year":"2001","journal-title":"Journal of European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0062|cit61","first-page":"184","article-title":"Premenstrual dysphoric disorder and work efficiency: Response to fluoxetine in a randomized clinical trial","volume":"42","author":"Trzepacz","year":"2001","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0061|cit62","first-page":"340S","article-title":"Premenstrual dysphoric disorder and work efficiency: Response to fluoxetine in a randomized clinical trial","volume":"2 Suppl","author":"Trzepacz","year":"2001","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0063|cit63","unstructured":"Gee M Bellew K Holland F Van Erp E Perera P McCafferty J Luteal phase dosing of paroxetine controlled release is effective in treating PMDD 156th Annual Meeting American Psychiatric Association, May 17-22 San Francisco, CA 2003 NR760"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0064|cit64","unstructured":"GlaxoSmithKline A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F717&studyId=CA9A3538-05F2-43D8-A1E2-342281DDD178&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ajog.2005.01.021","article-title":"Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder","volume":"193","author":"Steiner","year":"2005","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0066|cit66","unstructured":"GlaxoSmithKline A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg\/day and 20mg\/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F621&studyId=8696C1BE-93D7-4883-AD54-2BC6CF7740BB&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0067|cit67","unstructured":"Hamilton Health Sciences Corporation Luteal Phase Administration of Paroxetine for the Treatment of PMDD: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women NCT00620581 http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00620581 2008"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4088\/JCP.v69n0616","article-title":"Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women","volume":"69","author":"Steiner","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0069|cit69","first-page":"290","article-title":"Fluoxetine in the treatment of late luteal phase dysphoric disorder","volume":"52","author":"Stone","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0070|cit70","first-page":"331","article-title":"Fluoxetine in the treatment of premenstrual syndrome","volume":"26","author":"Stone","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub3-BIB0071|cit71","first-page":"41","article-title":"Sertraline in the treatment of premenstrual dysphoric disorder","volume":"32","author":"Yonkers","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0893-133X(96)00245-X","article-title":"Fluoxetine in the treatment of premenstrual dysphoria","volume":"16","author":"Su","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00004714-199810000-00007","article-title":"Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?","volume":"18","author":"Wikander","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0074|cit74","first-page":"339","article-title":"Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study","volume":"80","author":"Wood","year":"1992","journal-title":"Obstetrics and Gynecology"},{"issue":"12","key":"10.1002\/14651858.CD001396.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jama.1997.03550120043031","article-title":"Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment","volume":"278","author":"Yonkers","year":"1997","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4088\/JCP.v59n0206","article-title":"Treatment of PDD with sertraline during the luteal phase: a randomised, double-blind, placebo controlled crossover trial","volume":"59","author":"Young","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Young SA Hurt PH Benedek DM Howard RS Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double blind placebo controlled crossover trial American Psychiatric Association 150th Annual Meeting, San Diego USA 1997","DOI":"10.4088\/JCP.v59n0206"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4088\/JCP.v59n0206","article-title":"Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double blind placebo controlled crossover trial","volume":"59","author":"Young","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0079|cit79","first-page":"228","article-title":"Intermittant versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders","volume":"46","author":"Alpay","year":"2001","journal-title":"International Journal of Fertility"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004850-199300840-00018","article-title":"Treatment of premenstrual syndrome with fluoxetine: an open study","volume":"8","author":"Brandenburg","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0081|cit81","first-page":"235","article-title":"Trastorno disforico premenstrual: Tratamiento a largo plazo con fluoxetina y discontinuacion","volume":"25","author":"Gandara Martin","year":"1997","journal-title":"Actas Luso-Espanolas de Neurologia, Psiquiatria y Ciencias Afines"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0020-7292(98)00035-6","article-title":"A double blind trial of four medications to treat severe premenstrual syndrome","volume":"62","author":"Diegoli","year":"1998","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00007611-199305000-00003","article-title":"Open trial of fluoxetine therapy for premenstrual syndrome","volume":"86","author":"Elks","year":"1993","journal-title":"Southern Medical Journal"},{"issue":"003","key":"10.1002\/14651858.CD001396.pub3-BIB0084|cit84","first-page":"37","article-title":"Comparison between continuous and intermittent treatment with citalopram.....","volume":"26","author":"Fores Ramos","year":"2003","journal-title":"Salud Mental"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0086|cit85","unstructured":"Freeman EW Rickels K Sondheimer SJ Comparison of serotonergic and noradrenergic antidepressant medications in treatment of premenstrual syndrome (PMS) XXIst Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0087|cit86","unstructured":"Freeman EW Rickels K Sondheimer SJ Sertraline versus desipramine in PMS treatment 151st Annual Meeting of the American Psychiatric Association, Toronto, Canada"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0085|cit87","first-page":"7","article-title":"Sertraline versus desipramine in the treatment of premenstrual syndrome: an open label trial","volume":"57","author":"Freeman","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199902000-00002","article-title":"Full or half cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant","volume":"19","author":"Freeman","year":"1999","journal-title":"Journal of Cliniical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001396.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4088\/JCP.v61n0807","article-title":"Predictors of response to sertraline treatment of severe premenstrual syndromes","volume":"61","author":"Freeman","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/15246090260137635","article-title":"Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study","volume":"11","author":"Freeman","year":"2002","journal-title":"Journal of Womens Health & Gender-based Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4088\/JCP.v66n0616","article-title":"A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder","volume":"66","author":"Freeman","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0092|cit92","unstructured":"GlaxoSmithKline A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg\/day) Continuous Treatment for PMDD Patients Completing Studies 29060\/677, 688 or 689 http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F711&studyId=4A384A1A-46F7-4E8B-915B-4B324BB64491&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/npp.2008.86","article-title":"Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability","volume":"34","author":"Landen","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/jwh.2007.0491","article-title":"Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study","volume":"17","author":"Miller","year":"2008","journal-title":"Journal of Women's Health"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0095|cit95","first-page":"332","article-title":"Long term fluoxetine treatment of late luteal phase dysphoric disorder","volume":"55","author":"Pearlstein","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0096|cit96","unstructured":"Pearlstein T Haskett R Stout A Frank E Endicott J Sertraline improves psychosocial functioning in premenstrual dysphoric disorder 151st Annual Meeting of the American Psychiatric Association, 30th May- 4th June Toronto, Canada 1998"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4088\/JCP.v61n0205","article-title":"Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo","volume":"61","author":"Pearlstein","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0098|cit98","first-page":"161","article-title":"Fluoxetine in the treatment of PMS","volume":"48","author":"Rickels","year":"1990","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0099|cit99","first-page":"771","article-title":"Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria","volume":"33","author":"Steiner","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.1992.tb01440.x","article-title":"Clomipramine effectively reduces irritability and dysphoria: a placebo controlled trial","volume":"85","author":"Sundblad","year":"1992","journal-title":"Acta Psychiatrica Scandinavia"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/npp.1993.52","article-title":"Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo controlled trial","volume":"9","author":"Sundblad","year":"1993","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0924-977X(97)00404-5","article-title":"A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment","volume":"7","author":"Sundblad","year":"1997","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02244113","article-title":"Fluvoxamine in the treatment of menstrually related disorders","volume":"102","author":"Veeninga","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1440-1819.2007.01785.x","article-title":"Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols","volume":"62","author":"Wu","year":"2008","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199602000-00002","article-title":"Paroxetine as a treatment for premenstrual dysphoric disorder","volume":"16","author":"Yonkers","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0106|cit106","unstructured":"Yonkers KA Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00048854"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.jcp.0000203197.03829.ae","article-title":"Symptom-onset treatment for women with premenstrual dysphoric disorder","volume":"26","author":"Yonkers","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0108|cit108","unstructured":"Yonkers KA Altemus M Kornstein S Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00536198 2007"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0109|cit109","unstructured":"Yonkers KA Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00965562 2010"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0110|cit110","unstructured":"American College of Obstetricians and Gynecologists Premenstrual syndrome ACOG PracticeBulletin No. 15. Washington, DC: ACOG 2000"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0111|cit111","first-page":"774","article-title":"Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC:American Psychiatric Association; 2000. p. 774","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.maturitas.2012.03.007","article-title":"Premenstrual syndrome (PMS): A peri-menopausal perspective","volume":"72","author":"Baker","year":"2012","journal-title":"Maturitas 72"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0113|cit113","article-title":"Statistical Power Analysis in the Behavioral Sciences (2nd edition)","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2012.11081302","article-title":"Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5","volume":"169","author":"Epperson","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub3-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003415.pub4","article-title":"Progesterone for premenstrual syndrome","author":"Ford","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archgenpsychiatry.2008.547","article-title":"Time to relapse after short-term or long-term sertraline treatment for severe premenstrual syndromes","volume":"66","author":"Freeman","year":"2009","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/AOG.0b013e318236edf2","article-title":"Clinical subtypes of premenstrual syndrome and responses to sertraline treatment","volume":"118","author":"Freeman","year":"2011","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0118|cit118","unstructured":"GlaxoSmithKline Government Affairs Public Policy Patient Advocacy Public Disclosure of Clinical Research Downloaded from: http:\/\/www.google.co.nz\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.gsk.com%2Fpolicies%2FGSK-on-disclosure-of-clinical-trial-information.pdf&ei=lqIIUee4GuTDmQX9hoD4Ag&usg=AFQjCNEcA2G3XGrrh9BkqK1RedmQ53VgQg&bvm=bv.41642243,d.dGY"},{"issue":"7","key":"10.1002\/14651858.CD001396.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"566,569","DOI":"10.1017\/S1092852900016849","article-title":"Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough","volume":"13","author":"Halbreich","year":"2008","journal-title":"CNS Spectrum"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0120|cit120","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011 ] Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/CBO9781139696913","volume-title":"Psychological disorders in obstetrics and gynaecology for the MRCOG and beyond","author":"Ismail","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub3-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006414.pub2","article-title":"Chinese herbal medicine for premenstrual syndrome","author":"Jing","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10880-012-9299-y","article-title":"Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis","volume":"19","author":"Kleinstauber","year":"2012","journal-title":"Journal of Clinical Psychology in Medical Settings"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006586.pub4","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","author":"Lopez","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0002-9378(86)90808-2","article-title":"Trend analysis of the symptoms of 150 women with a history of th premenstrual syndrome","volume":"155","author":"Magos","year":"1986","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0126|cit126","unstructured":"DRUGDEX\u00ae Evaluations Micromedex.2 database Accessed 2.5.13 via University of Auckland library"},{"issue":"4","key":"10.1002\/14651858.CD001396.pub3-BIB0127|cit127","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010503","article-title":"Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome","author":"Naheed","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00737-010-0201-3","article-title":"Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus","volume":"14","author":"O'Brien","year":"2011","journal-title":"Archives of Womens Mental Health"},{"issue":"13","key":"10.1002\/14651858.CD001396.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2165\/00003495-200262130-00004","article-title":"Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder","volume":"62","author":"Pearlstein","year":"2002","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/9781435628168-6","article-title":"Prevalence, impact, on morbidity and burden of disease","volume-title":"The premenstrual syndromes: PMS and PMDD","author":"Pearlstein","year":"2007"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0002-9378(93)90079-X","article-title":"Diagnostic and treatment results from a south-eastern academic center-based premenstrual syndrome clinic: The first year","volume":"169","author":"Plouffe","year":"1993","journal-title":"Americal Journal of Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14656566.9.3.429","article-title":"The pharmacologic management of premenstrual dysphoric disorder","volume":"9","author":"Rapkin","year":"2008","journal-title":"Expert Opinion in Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/AOG.0b013e31816fd73b","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. A meta-analysis","volume":"111","author":"Shah","year":"2008","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD001396.pub3-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004632","article-title":"Vitex agnus castus for premenstrual syndrome","author":"Shaw","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub3-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005290","article-title":"Acupuncture for premenstrual syndrome","author":"Yu","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001396.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0140-6736(00)02754-9","article-title":"Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review","volume":"356","author":"Dimmock","year":"2000","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001396.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001396.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T07:48:51Z","timestamp":1645688931000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001396.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,7]]},"references-count":136,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001396.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001396.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,7]]}}}